SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 560-570

  Hassanein, Mohamed ^a   Hoeksema, Megan D ^a   Shiota, Masakazu ^a   Qian, Jun ^a   Harris, Bradford K ^a   Chen, Heidi ^a   Clark, Jonathan E ^a   Alborn, William E ^a   Eisenberg, Rosana ^a   Massion, Pierre P ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYL 4 NITROANILIDE; GLUTAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; PROTEIN INHIBITOR; PROTEIN SLC1A5; SODIUM; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ADENOCARCINOMA; ADULT; AMINO ACID TRANSPORT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CELL CYCLE PROGRESSION; CELL KINETICS; CELL MEMBRANE; CELL METABOLISM; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENDER; GLUTAMINE TRANSPORT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRACELLULAR TRANSPORT; LUNG CANCER; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AMINO ACID TRANSPORT SYSTEM ASC; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GLUTAMINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SEX FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84873363313     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2334     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-85.
3. Carbone DP. Molecular modalities in the treatment of lung cancer. Oncology 1999;13:142-7.
4. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
5. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 2003;63:1652-6.
6. Kikuchi T, Hassanein M, Amann JM, Liu Q, Slebos RJ, Rahman SM, et al. In-depth proteomic analysis of non-small cell lung cancer to discover molecular targets and candidate biomarkers. Mol Cell Proteomics 2012;11:916-32.
7. Witte D, Ali N, Carlson N, Younes M. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 2002;22:2555-7.
8. Albers A, Broer A, Wagner CA, Setiawan I, Lang PA, Kranz EU, et al. Na +transport by the neural glutamine transporter ATA1. Pflugers Arch 2001;443:92-101.
9. Broer S, Brookes N. Transfer of glutamine between astrocytes and neurons. J Neurochem 2001;77:705-19.
10. Bode BP, Kaminski DL, Souba WW, Li AP. Glutamine transport in isolated human hepatocytes and transformed liver cells. Hepatology 1995;21:511-20.
11. Bode BP, Souba WW. Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells. Ann Surg 1994;220:411-22.
12. Collins CL, Wasa M, Souba WW, Abcouwer SF. Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines. J Cell Physiol 1998;176:166-78.
13. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005;15:254-66.
14. Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 1986;46: 798-806.
15. Huber KR, Mayer EP, Mitchell DF, Roberts J. Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines. Br J Cancer 1987;55:653-6.
16. Rivera S, Azcon-Bieto J, Lopez-Soriano FJ, Miralpeix M, Argiles JM. Amino acid metabolism in tumour-bearing mice. Biochem J 1988;249: 443-9.
17. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010;107: 8788-93.
18. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011;481:380-4.
19. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 2011;108:19611-6.
20. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011;7:523.
21. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62: 3636-40.
22. Gazzola GC, Dall'Asta V, Franchi-Gazzola R, White MF. The clustertray method for rapid measurement of solute fluxes in adherent cultured cells. Anal Biochem 1981;115:368-74.
23. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
24. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 2007;293: C55-63.
25. Bjerregaard B, Holck S, Christensen IJ, Larsson LI. Syncytin is involved in breast cancer-endothelial cell fusions. Cell Mol Life Sci 2006;63: 1906-11.
26. Gazzola GC, Dall'Asta V, Bussolati O, Makowske M, Christensen HN.A stereoselective anomaly in dicarboxylic amino acid transport. J Biol Chem 1981;256:6054-9.
27. Esslinger CS, Cybulski KA, Rhoderick JF. Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg Med Chem 2005;13:1111-8.
28. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136:521-34.
29. Ovejera AA, Houchens DP, Catane R, Sheridan MA, Muggia FM. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6- diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res 1979;39: 3220-4.
30. Griffith OW, Mulcahy RT. The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol 1999;73:209-67.
31. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res 1994;54:1969s-75s.
32. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52: 711-60.
33. Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2004;286:G467-78.
34. Yang C, Sudderth J, Dang T, Bachoo RG, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009;69:7986-93.
35. DeBerardinis RJ. Keystone symposium: metabolism and cancer progression. Future Oncol 2010;6:893-5.
36. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-50.
37. Kekuda R, Torres-Zamorano V, Fei YJ, Prasad PD, Li HW, Mader LD, et al. Molecular and functional characterization of intestinal Na (+)-dependent neutral amino acid transporter B0. Am J Physiol 1997;272:G1463-72.
38. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 2011;3:468-78.
39. Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, et al. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. Anticancer Res 2011;31:3775-82.
40. Blond JL, Lavillette D, Cheynet V, Bouton O, Oriol G, Chapel-Fernandes S, et al. An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J Virol 2000;74: 3321-9.
41. Utsunomiya-Tate N, Endou H, Kanai Y. Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter. J Biol Chem 1996;271:14883-90.
42. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004;10:2499-511.